Provided by Tiger Trade Technology Pte. Ltd.

Axsome Therapeutics

199.90
+0.88000.44%
Volume:6K
Turnover:1.25M
Market Cap:10.47B
PE:-53.05
High:200.01
Open:199.00
Low:198.91
Close:199.02
52wk High:260.19
52wk Low:112.90
Shares:52.38M
Float Shares:43.83M
Volume Ratio:2.52
T/O Rate:0.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7685
EPS(LYR):-3.6821
ROE:-245.10%
ROA:-16.31%
PB:125.70
PE(LYR):-54.29

Loading ...

U.S. RESEARCH ROUNDUP-Arthur J. Gallagher & Co, Datadog, Oracle

Reuters
·
Jun 11

Axsome adopts executive severance, change-in-control plan effective June 5, 2026

Reuters
·
Jun 10

Axsome Therapeutics shareholders elect Saad, Mahony as Class II directors

Reuters
·
Jun 10

Axsome Therapeutics CEO Herriot Tabuteau disposes of USD 11.97 million in common shares

Reuters
·
Jun 10

Axsome CFO Nick Pizzie sells 33,000 shares for $7.92 million

Reuters
·
Jun 10

What Axsome Therapeutics (AXSM)'s SUNOSI Patent Settlements and Migraine Updates Mean For Shareholders

Simply Wall St.
·
Jun 06

Analysts Have Conflicting Sentiments on These Healthcare Companies: Amneal Pharmaceuticals (AMRX), Charles River Labs (CRL) and Axsome Therapeutics (AXSM)

TIPRANKS
·
Jun 04

Axsome Therapeutics Presents New SYMBRAVO® Data at the Americal Headache Society (AHS) 68th Annual Scientific Meeting

GlobeNewswire
·
Jun 04

BUZZ-U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway

Reuters
·
Jun 03

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 03

BUZZ-U.S. STOCKS ON THE MOVE-Ollie's Bargain Outlet Holdings, Steel Dynamics

Reuters
·
Jun 03

Axsome Therapeutics Reaches Settlement Over Sunosi Patent Dispute; Shares Rise Pre-Bell

MT Newswires Live
·
Jun 03

BUZZ-Axsome Therapeutics rises after co resolves patent litigation for sleep disorder drug

Reuters
·
Jun 03

BRIEF-Axsome Therapeutics Announces Settlement Resolving All Sunosi® (Solriamfetol) Patent Litigation

Reuters
·
Jun 03

Axsome settles all Sunosi patent litigation, sets generic entry for 2040

Reuters
·
Jun 03

Axsome Therapeutics - Resolves All Patent Litigation Related to Sunosi

THOMSON REUTERS
·
Jun 03

Axsome Therapeutics - Five Companies Granted Right to Sell Generic Sunosi From 2040, Subject to FDA Approval

THOMSON REUTERS
·
Jun 03

Axsome Therapeutics - Enters Settlement Agreement With First-to-File Generic Applicant for Sunosi

THOMSON REUTERS
·
Jun 03

Axsome Therapeutics director Mark Coleman disposes of common shares worth $4.06 million

Reuters
·
Jun 03

Axsome Therapeutics Partners with the Headache Alliance to Highlight the Impact of Migraine During Migraine and Headache Awareness Month

GlobeNewswire
·
Jun 01